Impact of pharmaceutical dosage form on stability and dissolution of roxithromycin

• Authors: Michał Ostrowski , Ewa Wilkowska , Tomasz Bączek
• Languages of publication: EN

Abstracts

EN

The behavior of dispersible tablets containing enteric-coated pellets and oral suspension, both containing roxithromycin, was investigated using dissolution tests in different media. The dissolution test was performed under different pH conditions. For both dosage forms investigated, the test was conducted at pH 1.2, 4.5, and 6.8. Additionally, for dispersible tablets, the test involving increasing pH was performed at pH 1.2 (acid stage) and afterwards at pH 6.8 (buffer stage). The extent of dissolution was measured using high-performance liquid chromatography (HPLC). In all cases tested, roxithromycin underwent rapid degradation at pH 1.2. Dispersible tablets displayed the features of modified release preparations with a non-complete dissolution during the test times in all media. Conversely, the oral suspension behaved as an immediate release preparation, with degradation at pH 1.2. However, the dissolution of the oral suspension at pH 4.5 and 6.8 was rapid and complete. The role of enteric-coated pellets is to mask the bitter taste of the active substance upon administration. However, the coating showed lack of resistance to media at pH 1.2. Therefore, dispersible tablets containing enteric-coated pellets are not pharmaceutically equivalent to the immediate-release oral suspension.

Keywords

EN

Roxithromycin; Dispersible tablets; Enteric-coated pellets; Oral suspension

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2010
• Volume: 5
• Issue: 1
• Pages: 83-90

Dates

published

1 - 2 - 2010

online

29 - 1 - 2010

Contributors

author

Michał Ostrowski

• R&D Department, Polfa Tarchomin SA, Fleminga 2, 03-176, Warszawa, Poland

author

Ewa Wilkowska

• R&D Department, Polfa Tarchomin SA, Fleminga 2, 03-176, Warszawa, Poland

author

Tomasz Bączek

• Department of Pharmaceutical Chemistry, Medical University of Gdańsk, Hallera 107, 80-416, Gdańsk, Poland

References

• [1] Young RA, Gonzales JP, Sorkinm EM, Roxithromycin. A review of its antibacterial activity. Pharmacokinetics properties and clinical efficacy, Drugs, 1989, 37, 8–41 http://dx.doi.org/10.2165/00003495-198937010-00002[Crossref]
• [2] Markham A, Faulds D, Roxithromycin: An update of its antimicrobial activity, pharmacokinetics properties and therapeutic use, Drugs, 1994, 48, 297–326 http://dx.doi.org/10.2165/00003495-199448020-00011[Crossref]
• [3] Mazzei T, Mini E, Novelli A, Chemistry and mode action of macrolides, J. Antimicrob. Chemother., 1993, 31, 1–9 http://dx.doi.org/10.1093/jac/31.1.1[Crossref]
• [4] Fournet M-P, Zini R, Deforges L, Duval J, Tillement J-P, Determination of binding parameters of macrolides, lincosamides, and streptogramins to Legionella pneumophilia, J. Pharm. Sci., 1987, 76, 153–156 http://dx.doi.org/10.1002/jps.2600760214[Crossref]
• [5] Kuenzi B, Segessenmann CH, Gerber AU, Postantibiotic effect roxithromycin, erythromycin and clindamycin against selected Gram-ppositive bacteria and Haemophilus influenze, J. Antimicrob. Chemother., 1987, 20, 39–46 [Crossref]
• [6] Gasc J-C, D’Ambrieres SG, Lutz A, Chantot J-F, New ether oxime derivatives of erythromycin A. A structure-activity relationship study, J. Antibiot., 1991, 44, 313–330 [Crossref]
• [7] Zhong D, Li X., Wang A., Xu Y., Wu S, Identification of the metabolites of roxithromycin in humans, Drug Metab. Dispos., 2000, 28, 552–559 [PubMed]
• [8] Huang H, Yu LH, Sun, TM, In vitro antibacterial activity of roxithromycin and its major metabolites, Chin. J. Antibiot., 2002, 25, 443–446
• [9] Sun J, Zhang T, Qiu F, Liu Y, Tang J, Huang H, He Z, Impact of pharmaceutical dosage forms on the pharmacokinetics of roxithromycin in healthy human volunteers, J. Antimicrob. Chemother., 2005, 55, 796–799 http://dx.doi.org/10.1093/jac/dki082[Crossref]
• [10] Ostrowski M, Wilkowska E, Baczek T, In vivo-in vitro correlation for amoxicillin trihydrate 1000 mg dispersible tablet, Dsrug Dev. Ind. Pharm., 2009, 35, 981–985 http://dx.doi.org/10.1080/03639040902737492[Crossref]
• [11] Hang S, Xing J, Hong D, pH-dependent geometric isomerisation of roxithromycin in simulated gastrointestinal fluids and in rats, J. Pharm. Sci., 2004, 93, 1300–1309 http://dx.doi.org/10.1002/jps.20023[Crossref]
• [12] Motta M, Ribeiro W, Ifa DR, Moares ME, Moraes MO, Corrado AP, De Nucci G, Bioequivalence evaluation of two roxithromycin formulations in healthy human volunteers by high performance liquid chromatography coupled to tandem mass spectrometry, Acta Physiol. Pharmacol. Ther. Latinoam., 1999, 49, 233–241 [PubMed]
• [13] Nakagawa Y, Itai S, Yoshida T, Nagai T, Physicochemical properties and stability in the acidic solution of a new macrolide antibiotic, clarithromycin in comparison with erythromycin, Chem. Pharm. Bull., 1992, 40, 725–728 [PubMed][Crossref]
• [14] Morimoto S, Misawa Y, Asaka T, Kondoh H, Watanabe Y, Chemical modification of erythromycins. VI. Structure and antibacterial activity of acid degradation products of 6-O-methylerythromycins A, J. Antibiot., 1990, 43, 570–573 [Crossref]

Identifiers

DOI

10.2478/s11536-009-0113-7